AMRI, in the process of consolidating its drug discovery services, is teaming up with life sciences giant PerkinElmer to accelerate a new biomedical hub in Buffalo, NY.
Contract drugmaker AMRI is shifting some of its focus to early-stage R&D, partnering up with a neighboring biotech to expand its capabilities in drug discovery.
Contract manufacturer AMRI has been reworking its manufacturing assets, picking up valuable pieces here and there and then sacrificing a less important one as it moves toward contract manufacturing and away from a reliance on royalties. Its most recent earnings suggest the strategy is paying off on the top line at least.
Contract drug developer AMRI, on the mend after a series of setbacks, posted a 38% sales boost to start the year, but the costs of an ongoing transition dragged it into the red for yet another quarter.
Contract drug developer AMRI is closing down a U.K. manufacturing operation as part of its across-the-board change in strategy, an effort to get back to growth after a rough string of quarters.
U.S. contract manufacturer AMRI says that it will follow through with plans to close its API manufacturing site in Holywell, U.K., a move that will mean the loss of 62 jobs.
Sixty-four jobs are at risk as a result of AMRI's proposal to close an API plant in Wales. A final decision for the plant will come after a consultation with employees and discussions on ways to reduce "redundancies" at the former Excelsyn facility.
Marred by bad weather and an ongoing transition, contract drug developer AMRI swung to a loss in the fourth quarter, but steady gains in revenue have the company optimistic about the coming year.
In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.
AMRI has extended a buying streak to build up its contract manufacturing capabilities, adding to its injectable drug operations in the process. The New York-based company will lay out $60 million to buy two facilities from drug development specialist Aptuit.